Strategic collaboration will enable preclinical assessment and inform clinical development strategy for Redx’s Porcupine (RXC006) and ROCK2 inhibitors for fibrotic diseases with high unmet medical need.
Psychiatry Consortium announces its first call for projects that focus on the identification of novel drug targets to address the unmet therapeutic needs of people with mental health conditions.
Cystic Fibrosis Syndicate in Antimicrobial Resistance launches
Psychiatry Consortium to address unmet patient needs.
Medicines Discovery Catapult and Waters partner to support UK medicines discovery with advanced technology solutions.
Medicines Discovery Catapult and LifeArc, leading forces driving UK innovation in drug discovery, announce their strategic partnership.
Driving innovation into state-of-the-art technologies such as Artificial Intelligence and Complex Cell Models is key to maintaining the UK’s global competitiveness.
Accelerating translation of more predictive cell models in drug discovery.
Chief.AI and Medicines Discovery Catapult awarded funding to make Artificial Intelligence accessible to all drug discovery researchers.
Medicines Discovery Catapult’s Virtual R&D Discovery Services platform announce twenty-two partnerships.
See how we can help support you with your next drug discovery project.
Speak to us